CBAY CymaBay Therapeutics, Inc. Stock Quote

CBAY [NASD]

Index	-	P/E	-	EPS (ttm)	-1.32	Insider Own	0.32%	Shs Outstand	87.80M	Perf Week	16.67%
Market Cap	175.81M	Forward P/E	-	EPS next Y	-1.27	Insider Trans	7.96%	Shs Float	80.97M	Perf Month	-22.22%
Income	-100.20M	PEG	-	EPS next Q	-0.31	Inst Own	78.60%	Short Float	2.78%	Perf Quarter	-37.87%
Sales	-	P/S	-	EPS this Y	-71.10%	Inst Trans	-0.43%	Short Ratio	4.38	Perf Half Y	-47.10%
Book/sh	1.22	P/B	1.72	EPS next Y	-20.40%	ROA	-62.40%	Target Price	10.33	Perf Year	-52.27%
Cash/sh	2.25	P/C	0.93	EPS next 5Y	-	ROE	-92.30%	52W Range	1.67 - 5.06	Perf YTD	-37.87%
Dividend	-	P/FCF	-	EPS past 5Y	-2.20%	ROI	-	52W High	-58.50%	Beta	1.14
Dividend %	-	Quick Ratio	13.70	Sales past 5Y	-	Gross Margin	-	52W Low	25.74%	ATR	0.14
Employees	60	Current Ratio	13.70	Sales Q/Q	-	Oper. Margin	-	RSI (14)	43.60	Volatility	6.11% 6.90%
Optionable	Yes	Debt/Eq	0.73	EPS Q/Q	-24.20%	Profit Margin	-	Rel Volume	1.58	Prev Close	1.90
Shortable	Yes	LT Debt/Eq	0.73	Earnings	May 12 AMC	Payout	-	Avg Volume	514.28K	Price	2.10
Recom	1.70	SMA20	0.77%	SMA50	-23.04%	SMA200	-37.86%	Volume	812,015	Change	10.53%

Apr-11-22

Resumed

Cantor Fitzgerald

Overweight

Aug-04-20

Reiterated

H.C. Wainwright

Buy

$9 → $13

Jul-31-20

Initiated

Piper Sandler

Overweight

$12

May-26-20

Upgrade

H.C. Wainwright

Neutral → Buy

May-12-20

Upgrade

SVB Leerink

Mkt Perform → Outperform

May-12-20

Upgrade

Stifel

Hold → Buy

$4 → $8

May-12-20

Upgrade

ROTH Capital

Neutral → Buy

$15

May-12-20

Upgrade

Raymond James

Mkt Perform → Outperform

May-12-20

Upgrade

Evercore ISI

In-line → Outperform

$15

Mar-13-20

Upgrade

Oppenheimer

Perform → Outperform

Mar-13-20

Upgrade

Cantor Fitzgerald

Neutral → Overweight

Nov-26-19

Downgrade

ROTH Capital

Buy → Neutral

$22 → $2

Nov-26-19

Downgrade

Raymond James

Strong Buy → Mkt Perform

Nov-26-19

Downgrade

H.C. Wainwright

Buy → Neutral

$16 → $2

Nov-26-19

Downgrade

Cantor Fitzgerald

Overweight → Neutral

$20 → $2

Nov-25-19

Downgrade

SunTrust

Buy → Hold

Nov-25-19

Downgrade

Stifel

Buy → Hold

Nov-25-19

Downgrade

Evercore ISI

Outperform → In-line

Jun-25-19

Initiated

Stifel

Buy

Jun-12-19

Upgrade

Raymond James

Outperform → Strong Buy

May-13-22 12:00AM	CymaBay Therapeutics Inc. (CBAY) Q1 2022 Earnings Call Transcript Motley Fool
May-12-22 04:06PM	CymaBay Reports First Quarter 2022 Financial Results and Provides Corporate Update GlobeNewswire
May-11-22 08:00AM	CymaBay Therapeutics Announces Presentations at Digestive Disease Week® 2022 GlobeNewswire -8.02%
May-06-22 09:37AM	How Many CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Shares Do Institutions Own? Simply Wall St.
May-05-22 04:01PM	CymaBay Therapeutics to Report First Quarter of 2022 Financial Results on Thursday, May 12, 2022 GlobeNewswire -9.05%
Apr-24-22 11:05AM	P&G may not be able to continue operations in Russia American City Business Journals
Apr-22-22 04:47PM	Barclays Suspends Until Further Notice Further Sales of the iPath ® Series B Bloomberg Natural Gas Subindex Total Return SM ETNs (the "ETNs") Business Wire
Apr-20-22 09:26AM	Procter & Gamble beats earnings expectations, raises outlook Yahoo Finance Video
07:44AM	P&G CEO doesn't see a recession after big quarter for consumer products giant Yahoo Finance
Apr-04-22 08:00AM	CymaBay Therapeutics Announces Publication of Results From a 52-Week, Open-Label, Phase 2 Study of Seladelpar in Patients With Primary Biliary Cholangitis GlobeNewswire
Mar-23-22 06:13PM	Health Check: How Prudently Does CymaBay Therapeutics (NASDAQ:CBAY) Use Debt? Simply Wall St.
Mar-17-22 04:25PM	CymaBay Announces Appointment of Éric Lefebvre, M.D. to Board of Directors GlobeNewswire
04:06PM	CymaBay Reports Fourth Quarter and Year Ended December 31, 2021 Financial Results and Provides Corporate Update GlobeNewswire
Mar-10-22 04:05PM	CymaBay Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 17, 2022 GlobeNewswire
Feb-10-22 08:00AM	CymaBay Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Jan-24-22 05:38PM	LCM Capital Management Inc Buys Southern Co, Advanced Micro Devices Inc, Diageo PLC, Sells ... GuruFocus.com
Jan-22-22 06:00AM	Trade Alert: The Chief Medical Officer Of CymaBay Therapeutics, Inc. (NASDAQ:CBAY), Dennis Kim, Has Just Spent US$61k Buying A Few More Shares Simply Wall St.
Jan-11-22 12:00PM	CymaBay Therapeutics Inc. (CBAY) Moves to Buy: Rationale Behind the Upgrade Zacks
Jan-04-22 01:38PM	Lvm Capital Management Ltd Buys Medtronic PLC, Zoetis Inc, Eaton Corp PLC, Sells AT&T Inc, ... GuruFocus.com
Dec-16-21 09:14AM	10 Micro-Cap Stocks to Buy According to Hedge Funds Insider Monkey
Nov-19-21 09:47AM	7 Penny Stocks With the Potential to 10X in 2022 InvestorPlace
Nov-18-21 08:00AM	CymaBay Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants GlobeNewswire
Nov-17-21 04:33PM	CymaBay Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants GlobeNewswire
Nov-15-21 08:00AM	CymaBay Therapeutics Long-term Open Label Study Finds Treatment with Seladelpar for Two Years Improves Key Liver Biomarkers in Patients with PBC GlobeNewswire
Nov-11-21 09:00AM	CymaBay Therapeutics Inc. (CBAY) Q3 2021 Earnings Call Transcript Motley Fool
08:00AM	CymaBay Therapeutics to Host Post-AASLD Key Opinion Leader Webinar on Seladelpar for Primary Biliary Cholangitis GlobeNewswire
Nov-10-21 05:35PM	CymaBay Therapeutics Inc. (CBAY) Reports Q3 Loss, Misses Revenue Estimates Zacks
04:06PM	CymaBay Reports Third Quarter and Nine Months Ended September 30, 2021 Financial Results and Provides Corporate Update GlobeNewswire
Nov-04-21 08:00AM	CymaBay Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Nov-03-21 04:05PM	CymaBay Therapeutics to Report Third Quarter 2021 Financial Results on Wednesday, November 10, 2021 GlobeNewswire +9.52%
Nov-01-21 07:07AM	What Type Of Shareholders Own The Most Number of CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Shares? Simply Wall St. +6.92%
Oct-06-21 11:21AM	2 Strong Buy Penny Stocks That Could Rally All the Way to $10 TipRanks +8.65%
Oct-01-21 08:00AM	CymaBay Therapeutics Announces Presentations at The Liver Meeting® 2021 GlobeNewswire
Sep-02-21 07:38AM	A Look At The Fair Value Of CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Simply Wall St.
Aug-30-21 08:00AM	CymaBay Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Aug-12-21 11:00PM	CymaBay Therapeutics Inc. (CBAY) Q2 2021 Earnings Call Transcript Motley Fool
04:06PM	CymaBay Reports Second Quarter and Six Months Ended June 30, 2021 Financial Results and Provides Corporate Update GlobeNewswire
Aug-05-21 04:01PM	CymaBay Therapeutics to Report Second Quarter 2021 Financial Results on Thursday, August 12, 2021 GlobeNewswire
Aug-02-21 10:29AM	CymaBay Secures $100M Non-Dilutive Funding To Fund Seladelpar Development Program Benzinga
08:00AM	CymaBay Announces $100 Million Non-Dilutive Financing with Abingworth GlobeNewswire
Jul-26-21 11:18AM	Were Hedge Funds Right About CymaBay Therapeutics Inc (CBAY)? Insider Monkey
Jul-20-21 09:10AM	New Strong Sell Stocks for July 20th Zacks
Jun-30-21 02:26AM	We Think CymaBay Therapeutics (NASDAQ:CBAY) Can Afford To Drive Business Growth Simply Wall St.
Jun-21-21 08:00AM	CymaBay Therapeutics Presents Positive PBC Data at the International Liver Congress 2021 GlobeNewswire
Jun-14-21 08:00AM	CymaBay Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Jun-09-21 08:00AM	CymaBay Therapeutics Announces Presentations During The International Liver Congress 2021 GlobeNewswire
May-18-21 08:00AM	CymaBay Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
May-17-21 08:30AM	CymaBay Therapeutics Inc. (CBAY) Q1 2021 Earnings Call Transcript Motley Fool
May-13-21 04:06PM	CymaBay Reports First Quarter 2021 Financial Results and Provides Corporate Update GlobeNewswire
02:30PM	CymaBay Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
08:00AM	CymaBay Welcomes Dennis D. Kim, MD, MBA as Chief Medical Officer GlobeNewswire
May-11-21 08:00AM	CymaBay Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire +8.88%
May-10-21 08:00AM	CymaBay Names Lewis Stuart Chief Commercial Officer GlobeNewswire -5.52%
May-06-21 08:00AM	CymaBay Therapeutics to Report First Quarter 2021 Financial Results on Thursday, May 13, 2021 GlobeNewswire
Apr-05-21 08:00AM	CymaBay Appoints Thomas Wiggans and Janet Dorling to Board of Directors GlobeNewswire
Apr-01-21 02:15AM	Is CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Popular Amongst Institutions? Simply Wall St.
Mar-27-21 01:30AM	CymaBay Therapeutics Inc. (CBAY) Q4 2020 Earnings Call Transcript Motley Fool
Mar-25-21 04:10PM	CymaBay Reports Fourth Quarter and Year End 2020 Financial Results and Provides Corporate Update GlobeNewswire
02:30PM	CymaBay Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Mar-12-21 08:00AM	CymaBay Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results on Thursday, March 25, 2021 GlobeNewswire
Mar-11-21 08:00AM	CymaBay Therapeutics to Present at the 2021 NASH-TAG Conference GlobeNewswire +5.50%
Feb-24-21 08:00AM	CymaBay Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Feb-10-21 08:00AM	CymaBay Therapeutics to Present at the SVB Leerink 10th Annual Global Healthcare Conference GlobeNewswire
Jan-04-21 09:27AM	5 Disruptive Biotech Stocks With Solid Long-Term Potential Zacks
Dec-31-20 11:25PM	CymaBay Therapeutics (NASDAQ:CBAY) Is In A Good Position To Deliver On Growth Plans Simply Wall St.
Dec-16-20 10:07PM	Is CBAY A Good Stock To Buy Now? Insider Monkey
Nov-16-20 04:01PM	CymaBay Therapeutics Announces Oral Late-Breaking Presentation of Positive Results from the ENHANCE Global Phase 3 Study Evaluating Seladelpar for Primary Biliary Cholangitis at The Liver Meeting® 2020 GlobeNewswire
Nov-11-20 08:00AM	CymaBay Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Nov-07-20 02:01AM	CymaBay Therapeutics Inc. (CBAY) Q3 2020 Earnings Call Transcript Motley Fool
Nov-05-20 04:05PM	CymaBay Reports Third Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire
02:30PM	CymaBay Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
08:00AM	CymaBay Announces Study to Evaluate the Potential for GPR119 Agonists to Prevent Hypoglycemia in Type 1 Diabetes GlobeNewswire
Nov-02-20 08:00AM	CymaBay Therapeutics Announces an Oral Late-Breaking Presentation of Results from the ENHANCE Global Phase 3 Study Evaluating Seladelpar for Primary Biliary Cholangitis at The Liver Meeting® 2020 GlobeNewswire
Oct-30-20 04:32PM	CymaBay Therapeutics to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 GlobeNewswire -5.35%
Oct-01-20 08:00AM	CymaBay Therapeutics to Present Data from its Phase 2 Study of Seladelpar in Patients with NASH at The Liver Meeting® 2020 GlobeNewswire
Sep-30-20 09:58AM	Implied Volatility Surging for CymaBay Therapeutics (CBAY) Stock Options Zacks
Sep-29-20 11:21AM	CymaBay Therapeutics Inc (CBAY): Hedge Funds Are Snapping Up Insider Monkey +8.59%
Sep-22-20 07:00AM	Milestone Pharmaceuticals Strengthens Board of Directors with Two New Appointments PR Newswire
Sep-03-20 04:05PM	CymaBay Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Aug-27-20 08:00AM	CymaBay Therapeutics Presents Positive Final Results From 52-Week Phase 2 Study in Primary Biliary Cholangitis at The Digital International Liver Congress 2020 GlobeNewswire -5.34%
Aug-20-20 08:00AM	CymaBay Therapeutics Announces Presentations During The Digital International Liver Congress 2020 GlobeNewswire
Aug-11-20 03:01AM	CymaBay Therapeutics Inc. (CBAY) Q2 2020 Earnings Call Transcript Motley Fool -17.10%
Aug-10-20 04:01PM	CymaBay Reports Second Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire +10.22%
Aug-05-20 03:31PM	Oppenheimer: These 3 Strong Buy Stocks Could Double, If Not More TipRanks
Aug-03-20 04:01PM	CymaBay Therapeutics to Report Second Quarter 2020 Financial Results on Monday, August 10, 2020 GlobeNewswire +37.46%
07:00AM	CymaBay Announces Positive Topline Results from ENHANCE for Seladelpar in Patients with Primary Biliary Cholangitis GlobeNewswire
Jul-23-20 08:00AM	FDA Lifts All Clinical Holds on Seladelpar GlobeNewswire +25.07%
Jul-13-20 03:05AM	Edited Transcript of CBAY earnings conference call or presentation 11-May-20 8:30pm GMT Thomson Reuters StreetEvents
Jul-05-20 09:44AM	Is CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Popular Amongst Institutions? Simply Wall St.
Jun-28-20 07:20PM	Hedge Funds Keep Selling CymaBay Therapeutics Inc (CBAY) Insider Monkey
Jun-19-20 08:00AM	CymaBay Therapeutics Presents Data at Digestive Disease Week 2020 Online Education GlobeNewswire +7.65%
Jun-18-20 08:45AM	Is the Options Market Predicting a Spike in CymaBay (CBAY) Stock? Zacks
Jun-09-20 05:53PM	Here's Why CymaBay Therapeutics Rose 109% in May Motley Fool
Jun-05-20 05:00PM	Notice of Change of Location of Annual Meeting of Stockholders to be Held on June 23, 2020 GlobeNewswire
Jun-02-20 10:22AM	The Zacks Analyst Blog Highlights: Aileron Therapeutics, Energy Focus, MicroVision, Mersana Therapeutics and CymaBay Therapeutics Zacks
Jun-01-20 08:34AM	5 Top Stocks Up 100%+ in May With More Room to Run Zacks
May-26-20 06:12PM	Is CymaBays Seladelpar Back in the Saddle? 5-Star Analyst Weighs In SmarterAnalyst
May-21-20 07:21AM	Will Good News Boost This Small-Cap Drug Company's Stock Even Higher? Motley Fool
May-15-20 08:29AM	Is CymaBay Therapeutics (CBAY) Stock a Solid Choice Right Now? Zacks
May-13-20 09:37AM	Do Options Traders Know Something About CymaBay Therapeutics (CBAY) Stock We Don't? Zacks

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta, which has completed Phase II clinical study for the treatments of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics; and CB-0406, which is in Phase I clinical trial for the inflammation disease/condition. Its preclinical stage product candidate is CB-001, a G protein-coupled receptor for omega-3 fatty acids, such as docosahexaenoic acid for the treatment of gut/liver disease. It has a license agreement with DiaTex, Inc. to develop and commercialize therapeutic products comprising halofenate and its enantiomers, derivatives, and analogs for the treatment of diseases; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
KIM DENNIS D	Chief Medical Officer	Jan 19	Buy	3.04	20,000	60,800	20,000	Jan 20 04:35 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience